Searched for
STRIDES PHARMA REVENUE GROWTH
Accenture cuts revenue outlook, stock crashes 17%Accenture has lowered its annual revenue growth forecast. Companies are still cautious about spending on technology. This is happening even...- Infosys ADRs crash over 8%, Wipro falls 6% after Accenture cuts annual revenue forecastInfosys and Wipro ADRs plunged following Accenture’s reduced FY26 revenue forecast. This downgrade highlights enterprise caution regarding ...
- Christy Mathai used market dip to buy insurance, logistics stocks; here's his sector-by-sector playbookFund Manager Christy Mathai sees easing war-driven inflation fears, expecting a shorter earnings hit. He's selectively adding to his portfo...
- Green economy companies top $10 trillion market capThe green economy has hit a record $10 trillion market value. Revenue from climate solutions grew significantly last year. Companies focuse...
- JLR projects revenue growth and return to profit in FY27, doubles down on USJaguar Land Rover anticipates a strong comeback in financial year 2027. The company projects a 13% revenue increase and a return to profita...
- JLR sets out path to double-digit revenue growth through greater propulsion flexibility, North America pushJaguar Land Rover is launching a new growth plan. The company will offer more engine choices, including electric and hybrid options, for it...
- Indian pharma market's double-digit growth momentum is likely to continue further: EquirusThe Indian Pharmaceutical Market is set for continued double-digit growth. May's performance showed strong demand across all therapies. Chr...
- Tamil Nadu's excise revenue lags behind Karnataka, Maharashtra: GovtTamil Nadu's excise duty collections significantly lag behind Karnataka and Maharashtra, showing the lowest absolute collection and slowest...
- States' expenditure rises 131% in 10 yrs on welfare, development: CAG ReportStates' spending surged 131 percent from 2015-16 to 2024-25. Welfare and development drove this growth. Revenue expenditure remained the la...
- Light at the end of the tunnel? Gautam Shah sees Nifty eyeing 25,500, bets on smallcaps, pharma and Adani stocksIndian equities are nearing a crucial turning point, with market veteran Gautam Shah suggesting a shift in focus beyond benchmark indices. ...
- India leads globally in AI-driven revenue growth expectations: BCG surveyIndian marketers anticipate significant AI-driven revenue growth. India leads globally in adopting agentic commerce, a new marketing approa...
- Quant Small Cap Fund raises stake in Adani Enterprises and 8 others, trims in Aurobindo Pharma and 4 moreQuant Small Cap Fund increased exposure to Adani Enterprises and eight other stocks in May while reducing holdings in Aurobindo Pharma and ...
- Revenue of auto ancillary firms grew at 11% CAGR during 2016-26: ReportAuto ancillary companies saw revenue grow at 11 percent annually from FY16 to FY26. Exports and increased vehicle content fueled this expan...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- ‘Outcome-based’ contracts risk revenue growth for tech firmsThe increasing adoption of AI is driving Indian IT firms and clients towards outcome-based contracts. While this shift aims to improve clie...
- Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...
- PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- Telecom revenue growth may slip to single digits without tariff hikeTelecom revenue growth may slow to single digits this year without tariff increases. Operators are delaying hikes due to inflation. A poten...
Load More
